Plasma kallistatin levels in patients with severe community-acquired pneumonia. - Test2 - elhamkhani - TriplyDB

Plasma kallistatin levels in patients with severe community-acquired pneumonia.

Plasma kallistatin levels in patients with severe community-acquired pneumonia.

http://www.wikidata.org/entity/Q33752812

about

Year in review 2013: Critical Care--respiratory infections Plasma kallistatin in critically ill patients with severe sepsis and septic shock.Year in review 2013: Critical Care--sepsis.Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis.Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis Kallistatin - the score beats the marker.Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection.Kallistatin protects against bleomycin-induced idiopathic pulmonary fibrosis by inhibiting angiogenesis and inflammation.Kallistatin suppresses cancer development by multi-factorial actions.Kallistatin levels in HIV-infected patients and effects of statin therapy.Discovery and Validation of a Six-Marker Serum Protein Signature for the Diagnosis of Active Pulmonary Tuberculosis.Protective Role of Kallistatin in Vascular and Organ Injury.Metabolic profiles in community-acquired pneumonia: developing assessment tools for disease severity.

P2860

Q27003346-B9602898-0A10-405B-90D9-1CE914775EAD Q33725117-6A404180-A28F-4C93-845B-68E06DB7777B Q35091080-ED19C09C-4B4D-4E18-94A1-94B1791259FA Q35877298-2608CD7C-A8F1-4881-9F9E-C172E3E3B982 Q35960792-F8407BBC-97AD-4E21-9B11-04F9EBF5242B Q36237963-68C798CC-1DDA-46DE-AAB5-B4EA126B1F3B Q36902902-CDB3563B-0980-45CF-BE0E-6D47D6B8E83D Q37263454-A9359035-2587-4EB6-9F26-40683DBDDDA1 Q37732963-6B765169-6103-428C-8E90-A68DC1EA3E85 Q39252905-A9A9B63B-DAA3-4121-B599-BE1940720FE1 Q42101794-100D1E4B-2CA0-4276-967C-7F2C66092F90 Q42285243-8DE06BA5-3F24-4534-83C2-C95A4EFEE73F Q42360588-0478980C-7D0B-4BCC-B36A-77B0CE38288D Q55069453-1553A538-4BE5-4B95-A4DB-40DB62C017E2

P2860

Plasma kallistatin levels in patients with severe community-acquired pneumonia.

http://www.wikidata.org/entity/Q33752812

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Plasma kallistatin levels in patients with severe community-acquired pneumonia.

@ast

Plasma kallistatin levels in patients with severe community-acquired pneumonia.

@en

type

label

Plasma kallistatin levels in patients with severe community-acquired pneumonia.

@ast

Plasma kallistatin levels in patients with severe community-acquired pneumonia.

@en

prefLabel

Plasma kallistatin levels in patients with severe community-acquired pneumonia.

@ast

Plasma kallistatin levels in patients with severe community-acquired pneumonia.

@en

P1433

Q33752812-A0A3B6EF-9A3A-44E5-8225-E9DF0475CFAD

P1476

Q33752812-87BCB166-71AA-4F4B-9196-11105BDC8CEA

P2093

Q33752812-3B8F5237-2CB8-48DC-AB17-A31EBE17F616

Q33752812-9560634B-078D-4130-92BF-88290E11D36D

Q33752812-9F8ADE15-D461-4887-9B97-CE6CAF1E5B50

Q33752812-A170FF14-809C-45A9-AEBB-83CAAAF25D7A

Q33752812-B8853DDB-3B53-45F9-8237-9FCBEB52FB7F

Q33752812-C2934083-8C36-440C-A963-AAD79FE99494

Q33752812-CBE6F444-745C-4D5B-AFEF-1F348668B192

P2860

Q33752812-0070DAA4-24FC-4F3F-A9C1-BCACAE899AB9

Q33752812-01B62C90-52C9-47F8-899D-6ED71C011D38

Q33752812-01CCD5F0-9FC7-4752-98BD-E4A1D42DEE2F

Q33752812-1C74CB76-EECA-49FF-A400-F7F3A04D2A70

Q33752812-3F0DE29A-B94F-43AE-9867-6D75980855BB

Q33752812-43496580-971F-4FB2-BBB6-DD4215196BAE

Q33752812-4D64240F-90FE-4578-BD7A-B82096985760

Q33752812-50204EA1-C42E-4FC2-A0A3-83547FD1C33D

Q33752812-53676333-0B96-4FA3-B4E5-7ACCA7DC6125

Q33752812-579E22D4-A2D9-4A3E-9D47-4E2202D9CA33

P2888

Q33752812-3E4AA9AD-233A-4E3A-B42E-84E4309F3F42

P304

Q33752812-2BE97CCD-1977-4AEC-BC13-B51E8803BC54

P31

Q33752812-4F4978B2-1372-4AD9-95C7-EE23A050CF0A

P356

Q33752812-1C9958F5-01AE-4486-8358-DED7B701D86A

P433

Q33752812-8E68F92C-ABC2-4C91-9F49-5AE52EB9BE74

P478

Q33752812-5B3346ED-BB55-4148-8FB4-8C80D3BD7A9A

P577

Q33752812-050BE554-B73B-454A-92D8-241611EEE8DC

P5875

Q33752812-94941951-6415-44F2-8E0E-57A98ED3EBAE

P6179

Q33752812-A89A376E-040C-4114-8726-1991253978BE

P698

Q33752812-B9F200C9-FE2F-4D4F-A6E8-45554EDEA52F

P921

Q33752812-B317E304-9199-4970-AF00-CF8EDCB0BAEE

P932

Q33752812-97627C0B-30A8-49C5-A57E-6468198AABDD

P356

P1433

P1476

Plasma kallistatin levels in patients with severe community-acquired pneumonia.

@en

P2093

Chang-Wen Chen

http://www.w3.org/2001/XMLSchema#string

Chiou-Feng Lin

http://www.w3.org/2001/XMLSchema#string

Julie Chao

http://www.w3.org/2001/XMLSchema#string

Lee Chao

http://www.w3.org/2001/XMLSchema#string

Shiou-Ling Lu

http://www.w3.org/2001/XMLSchema#string

Wei-Chieh Lin

http://www.w3.org/2001/XMLSchema#string

Yee-Shin Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study

Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

APACHE II: a severity of disease classification system

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine

Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation.

Contact system activation in severe infectious diseases.

Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose intraperitoneal aprotinin.

Kallistatin is a new inhibitor of angiogenesis and tumor growth.

Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease.

P2888

P304

R27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC12507

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235439752

http://www.w3.org/2001/XMLSchema#string

P6179

1000564596

http://www.w3.org/2001/XMLSchema#string

P698

23394256

http://www.w3.org/2001/XMLSchema#string

P921

P932

4056893

http://www.w3.org/2001/XMLSchema#string